CHMP recommends for approval generic version of Atripla

At its June meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection. Summary of opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is available here. [gview ...

June 27, 2017
EMCDDA and ECDC join forces to address the challenge of hepatitis

EMCDDA and ECDC join forces to address the challenge of hepatitis

Hepatitis and other drug-related infectious diseases will be the focus of ‘Hepatitis week’, taking place at the EU drugs agency (EMCDDA) in Lisbon from 12–16 June 2017. The initiative will bring together some 100 specialists from: EU Member States, candidate and potential candidate countries to ...

June 14, 2017
WHO Global hepatitis report, 2017

WHO Global hepatitis report, 2017

In May 2016, the World Health Assembly endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis 2016–2021. The GHSS calls for the elimination of viral hepatitis as a public health threat by 2030 (reducing new infections by 90% and mortality by 65%). This WHO Global ...

May 30, 2017
News  WHO Global  
2017 Post-EASL Report

2017 Post-EASL Report

As chronic hepatitis C virus (HCV) drug development approaches the end-game following the launch of the first pan-genotypic regimen Epclusa (; Gilead), recent and upcoming advances in chronic hepatitis B virus (HBV) treatment emerged as an important focus of the International Liver Conference (ILC) 2017, ...

May 18, 2017
Genetic study reveals how hepatitis C interacts with humans

Genetic study reveals how hepatitis C interacts with humans

A big data study of hepatitis C and more than 500 patients with the virus has opened the way for a better understanding of how the virus interacts with its human hosts. Researchers at the University of Oxford have for the first time developed a method ...

April 12, 2017

Decompensation more likely in women with acute HBV than men

Women, especially those 50 years or older, with overt acute hepatitis B were significantly more likely to develop decompensation, according to the results of a recent study. “This is an unexpected finding. The results suggest that HBV preventive measures are even more important for females,” Ming-Ling ...

April 06, 2017

Europe-wide action challenging patent on key hepatitis C drug

Patent opposition aims to increase affordable access to hepatitis C drug sofosbuvir for millions Rome/Geneva, 27 March 2017 – The international medical humanitarian organisation Médecins Sans Frontières (MSF) has today filed a patent challenge on the hepatitis C drug sofosbuvir with the European Patent Office (EPO) ...

March 28, 2017
EATG  News  

Abnormal bone metabolism with tenofovir for HBV infection

Patients receiving long-term tenofovir therapy for hepatitis B virus (HBV) infection have an increased risk for abnormalities in bone metabolism, such as low serum phosphate, according to a study published in the Annals of Hepatology.1 Tenofovir, a first-line antiviral agent for HBV, is generally well-tolerated, although ...

March 21, 2017

ACIP recommends single-dose revaccination for infants born to HBV-infected mothers

The Advisory Committee on Immunization Practices voted today (February 22) in favor of a single-dose alternative to 3-dose revaccination for infants born to hepatitis B surface antigen-positive mothers who failed to respond to the initial hepatitis B vaccination series. In a 13-1 vote, with one recusal, ...

February 28, 2017

WHO guidelines on hepatitis B and C testing

Overview Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection ...

February 22, 2017
EATG  News  WHO Global